Sung Pamela J, Luger Selina M
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd., South Pavilion 12th floor, Philadelphia, PA, 19104, USA.
Curr Treat Options Oncol. 2017 Jan;18(1):1. doi: 10.1007/s11864-017-0447-3.
New technology and improved understanding of the pathogenesis of acute leukemias have allowed for sensitive detection of minimal residual disease (MRD). Despite many years of research demonstrating the prognostic value of MRD, there is no standard of care for measurement of MRD in acute myeloid leukemia. The techniques for assessment are continuing to improve at a rapid pace; however, the benefit of risk-adapted approaches for MRD positive disease remains a major question. This review focuses on recent methodological advances for MRD detection, the role of MRD in prognostication, and current application of the available evidence in guiding therapy decisions.
新技术以及对急性白血病发病机制的深入理解，使得对微小残留病（MRD）的灵敏检测成为可能。尽管多年研究已证实MRD具有预后价值，但在急性髓系白血病中，尚无用于检测MRD的标准治疗方案。评估技术正在迅速改进；然而，针对MRD阳性疾病的风险适应性治疗方法的益处仍是一个主要问题。本综述重点关注MRD检测的最新方法进展、MRD在预后评估中的作用，以及现有证据在指导治疗决策方面的当前应用。
